Full-Time

DevSecOps Engineer

Posted on 11/30/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Onsite role; may require working outside standard hours to align with business hours.

Category
DevOps & Infrastructure (2)
,
Requirements
  • Demonstrated 2+ year of practical experience building, maintaining, and securing CI/CD pipelines (preferably using GitLab CI or similar tools)
  • Proven ability to develop automation scripts and tooling using languages like Python, Bash, Go, or JavaScript
  • Experience deploying and operating Infrastructure as Code (IaC) with Terraform or CloudFormation in cloud or hybrid environments
  • Direct involvement in integrating security tools (SAST, DAST, SCA, secrets scanning) into automated build and release workflows
  • Exposure to Kubernetes-based environments and monitoring toolchains such as Dynatrace, Grafana, or ELK is a plus
  • Ability to work independently on technical challenges while collaborating across security, development, and operations teams
  • 5 to 9 years of Computer Science, Information Technology or related field experience
  • Proficiency in GitLab CI/CD for secure pipeline development and automation
  • Strong experience with security tools like SAST, DAST, SCA, and secrets scanning
  • Knowledge of IaC practices using Terraform or CloudFormation
  • Solid scripting/programming skills in Python, Bash, Go, or JavaScript
  • Exposure to AI/ML solutions in DevSecOps (e.g., anomaly detection, automated remediation, predictive monitoring)
Responsibilities
  • Design, code, and maintain secure CI/CD pipelines using GitLab CI in hybrid and multi-cloud environments
  • Write high-quality, reusable, and testable code in languages such as Python, Go, JavaScript, or Bash to automate CI/CD workflows, infrastructure provisioning, and security enforcement
  • Develop custom DevSecOps utilities, GitLab runners, and dynamic pipeline templates
  • Maintain and scale Infrastructure as Code (IaC) using Terraform, CloudFormation, and Ansible
  • Integrate security automation tools (SAST, DAST, SCA, secrets scanning, IaC scanning) into the development and deployment pipelines
  • Build tooling for container and API security, including vulnerability scanning and policy enforcement
  • Partner with product security and cloud teams to implement RBAC, IAM, encryption, and compliance-by-design controls
  • Develop and maintain monitoring and observability solutions using Dynatrace, Prometheus, Grafana, ELK, or similar tools
  • Drive implementation of SLOs, SLIs, and automated alerting within CI/CD workflows
  • Contribute to incident response and root cause analysis with a focus on long-term resilience through automation
  • Support adoption of AI/ML-based DevSecOps tools for anomaly detection, policy enforcement, and risk forecasting
  • Work with platform leads to integrate intelligent insights into day-to-day operations
  • Mentor junior engineers and DevOps practitioners, fostering a culture of secure coding and software craftsmanship
  • Lead technical design discussions, evaluate open-source and commercial tools, and influence technology decisions
  • Work closely with product owners, engineering teams, cybersecurity, and platform teams to define and align secure delivery models
  • Coordinate with external vendors and internal stakeholders to ensure alignment on DevSecOps objectives
  • Participate in Agile and SAFe delivery processes—including sprint planning, stand-ups, retrospectives, and PI planning—to ensure security and platform reliability are embedded across development cycles
Desired Qualifications
  • Kubernetes workload security (EKS/AKS), including RBAC and network policies
  • Experience with policy-as-code (OPA, Kyverno) and IaC security scanning (Checkov, tfsec)
  • Familiarity with hybrid/multi-cloud environments (AWS, Azure)
  • Awareness of FinOps and cost-aware pipeline operations
  • Certified DevSecOps Professional (CDP)
  • GitLab CI/CD Specialist
  • Certified Kubernetes Security Specialist (CKS)
  • Attention to detail and security best practices
  • Effective collaborator across engineering, security, and operations teams
  • Self-driven with strong analytical and troubleshooting abilities
  • Passion for automation and continuous improvement

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE